( MENAFN - GlobeNewsWire - Nasdaq) CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the“Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in“Webinar Wednesday” hosted by Lantern Pharma on October 30, 2024.
Andrew Mazar, Ph.D., Chief Operating Officer of Actuate Therapeutics, and Joseph McDermott, Ph.
D, Lantern's computational biologist will discuss the multi-year research and development collaboration that is accelerating the development of Actuate's lead drug candidate, elraglusib, and enabling the screening for additional biomarkers to assess and predict its therapeutic activity and clinical outcomes. To register for the webinar, please use the following link: Elraglusib is a novel GSK-3β inhibitor currently being evaluated in Phase 2 Trial in metastatic pancreatic cancer (NCT03678883) and Phase 1/2 Trial (NCT04239092) in Ewing Sarcoma (EWS) and EWS-related sarcomas. About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate's lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoti.
